Denosumab News and Research

RSS

Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone.

Deadly brain cancer erodes skull bone and alters immune marrow

Scientists at Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have shown for the first time that glioblastoma-the deadliest form of brain cancer-affects not just the brain but also erodes the skull, alters the makeup of skull marrow, and interferes with the body's immune response.

3 Oct 2025

Adults over 80 benefit from osteoporosis medications

People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, Calif.

12 Jul 2025

Bone medications and steroids linked to increased risk of jaw disease

Certain medications used in the treatment of bone conditions, particularly when combined with corticosteroids, may significantly increase the risk of a rare but serious jaw disease.

3 Jun 2025

Clinical trial against breast cancer explores the potential anti-tumor role of denosumab

Science and society collaboration is essential for scientific progress, especially in the health and biomedical fields where basic researchers, clinicians and patients are involved, as shown by the initial results of D-BIOMARK.

16 May 2025

Clinical trial investigates osteoporosis medication for type 1 diabetes

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a top research center for diabetes and other life-threatening illnesses, is leading a phase 1/2 clinical trial investigating an osteoporosis medication as a way to improve beta cell health in people with early type 1 diabetes.

19 Mar 2025

47th annual San Antonio Breast Cancer Symposium kicks off in December

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), is hosting the 47th annual San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center on Dec. 10-13.

9 Dec 2024

Study finds link between industry payments to oncologists and non-recommended cancer treatments

Patients with cancer whose oncologist receives payments from industry appear more likely to receive some non-recommended and low value treatments, finds a US study published by The BMJ today.

25 Oct 2023

COVID-19 pandemic fails to deter osteoporosis treatment initiation: New study reveals steady rates

Whether patients with newly diagnosed osteoporosis received delayed pharmacologic treatment due to the COVID-19 pandemic.

18 Sep 2023

New drug could overcome resistance to CDK4/6 inhibitors in breast cancer

Brest cancer is the most common cancer in women. Among breast tumors that spread to other organs (develop metastasis), 70% belong to a variant, called luminal, whose cells are sensitive to the female sex hormones estrogen and progesterone. In fact, the tumor forms when these hormones order the cells to divide.

14 Jul 2023

New treatment for fibrous dysplasia shows promising results in NIH clinical trial

A clinical trial at the National Institutes of Health found that a medication, denosumab, significantly reduced abnormal bone turnover in adults with fibrous dysplasia, a rare disease marked by weak and misshapen bones.

4 Apr 2023

Denosumab may benefit postmenopausal patients with hormone receptor-negative breast tumors and RANK protein expression

The drug denosumab is currently used to treat osteoporosis and bone metastases. For more than a decade, its potential therapeutic benefit in the treatment of breast cancer has also been studied.

7 Mar 2023

Experts provide first framework for treating hypercalcemia of malignancy in adults

Experts provide the first framework for treating a common and life-threatening metabolic complication of cancer known as hypercalcemia of malignancy in the Endocrine Society's new Clinical Practice Guideline.

21 Dec 2022

Researchers discover osteogenetic oligodeoxynucleotide that promotes bone differentiation

Bone tissue homeostasis is maintained by a balance between bone formation by osteoblasts and bone resorption by osteoclasts.

23 May 2022

Advancements in the diagnosis and treatment of prostate cancer are saving more lives

Prostate cancer is the most common type of cancer among men in the United States aside from skin cancer, according to the Centers for Disease Control and Prevention.

8 Sep 2021

Study: One in six men with advanced prostate cancer experiences reduced sense of smell and taste

One in six men being treated for advanced prostate cancer experiences a reduced sense of smell and taste, a symptom that could cause increased anxiety among patients because it is also a side effect of COVID-19, according to Tulane researchers.

16 Mar 2021

Osteoporosis drug increases bone mineral density in the hip and lumbar spine

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.

6 Nov 2020

Some of the main osteoporosis treatments could have a protective effect against COVID-19

Some of the principal treatments for osteoporosis, denosumab, zoledronate and calcium, could have a protective effect against COVID-19 in patients who take them, specifically a 30 to 40% reduction in the rate of infection, according to the results of a joint study by Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University and the Pere Virgili Health Park.

3 Nov 2020